SOLASTA Bio files first US product and posts strong field demo under heavy whitefly pressure

SOLASTA Bio has submitted its first peptide-based insecticide for US registration, with EPA and California regulators now reviewing the package. The company also said a Georgia field demo showed visible crop protection performance during a whitefly surge not seen locally in more than a decade.

Why it matters: - SOLASTA Bio is trying to bring a peptide-based insecticide platform into the US market with a faster regulatory path than conventional chemistry. - The first filing targets aphids in leafy greens and vegetable crops, where resistance and tighter limits on traditional insecticides are increasing pressure on growers. - The field demo suggests the lead product can perform under severe pest pressure, a key hurdle for commercial adoption.

What happened: - SOLASTA Bio submitted regulatory packages for its peptide active ingredient and first end-use product to the US Environmental Protection Agency and the California Department of Pesticide Regulation. - The lead product is now under concurrent review by both regulators. - The submission follows the EPA's classification of SOLASTA Bio's lead peptide as a biochemical, which can support a faster and more cost-effective review than conventional insecticides. - The company hosted investors and partners in Georgia in early October for its second field demonstration event.

The details: - The first registration is aimed at aphid control in leafy greens and vegetable crops. - SOLASTA Bio's lead active ingredient is a nature-identical peptide selected for consistent aphid efficacy across multiple crops in field and greenhouse trials. - The peptide has a benign ecotoxicology profile, does not bioaccumulate, and showed no impact on beneficial species or plant health. - SOLASTA Bio is also seeking recognition from the Insecticide Resistance Action Committee for the technology as an entirely new mode of action. - The company said that designation would give US growers another option for rotating products to manage pest resistance. - The Georgia demo included field evaluations against aphids and whiteflies, plus selected peptides targeting Lepidoptera on different crops. - Local whitefly populations were reported at levels not seen in more than a decade. - Across the aphid, whitefly and lepidopteran evaluations, treated plots showed visible reductions in leaf-feeding damage and clearer improvements in plant vigor, health and appearance. - Visitors saw the treatment differences first-hand in the field. - SOLASTA Bio also cited a growing portfolio of US, European and rest-of-world patents. - The company completed an oversubscribed $14 million Series A funding round in 2024. - Backers in that round included Forbion BioEconomy Fund, Corteva Catalyst and FMC Ventures.

Between the lines: - SOLASTA Bio is positioning its technology as both a crop-protection tool and a resistance-management tool, which matters as aphids and whiteflies become harder to control. - The company is using field performance under extreme pest pressure to support its commercialization story, not just its regulatory case. - The combination of patent coverage, outside investment and active regulatory review suggests the company is moving from research toward market entry.

What's next: - The EPA and California regulators will continue reviewing the registration packages. - SOLASTA Bio will likely push for IRAC recognition and prepare for the commercial rollout of its first product if approvals move forward. - The company's pipeline is expected to follow its lead product as it moves toward commercialization.

The bottom line: - SOLASTA Bio has crossed a key US regulatory threshold and is now trying to prove its peptide insecticide can scale from promising field data to commercial farm use.